DNA Vaccine Delivery - Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors. - BioPharm International


DNA Vaccine Delivery
Development of the ideal DNA vaccine requires the optimization of delivery strategies and plasmid vectors.

BioPharm International Supplements
Volume 24, Issue 10, pp. s12-s18


Figure 2: Oral recombinant vaccine delivery using live bacterial vectors. (a) The live bacterial vectors (LBVs) are ingested and travel into the small intestine, where they invade the lining of the ileum through M cells and enter Peyer’s patches. (b) The LBVs invade antigen presenting cells and are phagocytosed. Shigella can escape the phagosome and enter the cytoplasm, while Salmonella modifies the phagosome and persists until it is digested by fusion with a lysosome. MHC is major histocompatibility complex.
The oral route for vaccination avoids needles and reduces the logistical issues and costs of implementing vaccination programs requiring trained healthcare professionals, which would be particularly beneficial in developing countries. Oral vaccination also stimulates a mucosal immune response, which is important because mucosal surfaces are a more common route of entry for many pathogens than is the skin. Much of the research in oral DNA vaccine delivery has focused live bacterial vectors (LBVs) derived from attenuated bacterial pathogens Salmonella and Shigella, enteric species that are able to replicate the high copy-number DNA vaccine plasmids normally produced in E. coli. These attenuated pathogens carry mutations of biosynthetic or invasive genes that eliminate their pathogenicity and ability to persist in host tissues or the environment.

LBVs that have been ingested travel from the stomach into the small intestine. Here, Salmonella and Shigella invade microfold (M) cells and enter lymphatic nodules called Peyer's patches. (see Figure 2). Once inside the Peyer's patches, the bacteria become targets for (or actively enter) macrophages, where they are internalized in membrane-bound phagosomes. At this point, one of two strategies is employed: Shigella escapes from the phagosome into the cytoplasm, while Salmonella alters the composition of the phagosome to survive and replicate (14). However, the precise mechanism of DNA vaccine delivery using bacterial vectors is not understood. For Shigella, the cells are thought to eventually lyse in the cytoplasm, releasing the DNA vaccine plasmids which are then transported to the nucleus by the host cell. Attenuating mutations that increase the rate of cell lysis have been shown to improve DNA vaccine delivery using Shigella flexneri. For phagosome-bound Salmonella, the potential mechanism is less obvious, but could be due to a bystander effect in which DNA released from host cells that have undergone apoptosis due to Salmonella invasion is carried to APCs in membrane blebs (14). As with other DNA delivery routes, once the plasmid enters the nucleus, the antigen gene is expressed, and the protein processed for MHC presentation. Another advantage of bacterial vectors is potent immunostimulatory properties, due mainly to the lipid A (endotoxin) in the cell membranes, which eliminates the need for an adjuvant. The direct targeting of the mucosal immune system means that vector-directed immune responses are not likely to inhibit the repeated use of live bacterial vectors.

Drug development suffers from the high attrition rate in translating promising preclinical results in animal models into success in human clinical trials. One variable in DNA vaccine development is the relative dose between preclinical and clinical subjects. For example, a DNA vaccination by conventional needle injection of a 20 g mouse typically requires 100 g of DNA to generate a protective immune response. To scale this to a 70-kg human would involve injecting 350 mg, which is prohibitive in terms of both the volume required and the associated cost (15). A typical vaccine dose used in human clinical trials is 2–4 mg DNA, which represents only 0.5–1% of the scaled dose. The extent to which the lack of scalability has affected human DNA vaccine development is debatable, as the first vaccine approved was effective in an even larger animal: the horse. But in contrast, Salmonella-based approaches use the same dose in terms of bacteria and plasmid DNA in humans as in mice. This similarity allows the murine dose to be representative, because S. enterica serovar Typhimurium in mice mimics the invasion and pathogenicity of S. enterica serovar Typhi in humans.

As with Shigella, Listeria monocytogenes has the ability to invade M cells and escape from the phagosome, and has been used to demonstrate DNA vaccine delivery, although it cannot replicate the high copy-number plasmids that are universally used as DNA vaccines. E. coli strains have also been used as DNA vaccine vectors, having been genetically modified to express the invasion and phagosomal escape proteins from its pathogenic relatives.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here